Physician profile
Cindy Brown
NPI 1760728554
$3,280.89
in general payments reported to CMS, 2019-2025
25 companies · $1,562 in 2025
The $1,562 reported for 2025 was more than what 92% of Family Health providers received nationally (typical 2025 total: $209).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $213 · 2022: $207 · 2023: $309 · 2024: $991 · 2025: $1,562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,861.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,861.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $583.20 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $576.17 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $302.23 | 2025 | Caplyta |
| Lilly USA, LLC | $275.62 | 2022-2024 | Zepbound |
| Sanofi-Aventis U.S. LLC | $243.38 | 2024-2025 | |
| Medtronic, INC. | $162.00 | 2025 | Percept PC Brainsense |
| Novo Nordisk INC | $135.96 | 2021-2025 | Wegovy, Ozempic |
| Actelion Pharmaceuticals US, INC. | $123.71 | 2024 | Uptravi, Opsumit |
| Phathom Pharmaceuticals, INC. | $116.43 | 2025 | Voquezna |
| Biomerieux INC | $103.00 | 2025 | Filmarray |
| Exact Sciences Corporation | $101.48 | 2023-2024 | Cologuard Collection Kit |
| Corcept Therapeutics | $100.80 | 2024 | Korlym |
| Radius Health, INC. | $94.05 | 2025 | Tymlos |
| Amgen INC. | $86.16 | 2021 | |
| Ge Healthcare | $50.02 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $38.07 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Axsome Therapeutics, INC. | $33.67 | 2023 | Sunosi |
| Indivior INC. | $27.59 | 2022 | |
| Astellas Pharma US INC | $22.59 | 2025 | Vyloy |
| Idorsia Pharmaceuticals US INC | $20.71 | 2023 | Quviviq |
| Xeris Pharmaceuticals, INC. | $20.48 | 2023 | Keveyis |
| Servier Pharmaceuticals LLC | $18.24 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $16.52 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.94 | 2021 | |
| Antares Pharma, INC. | $13.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.